Inherited cancer syndromes are individually rare but collectively important as they impose a significant impact on affected families and national health care costs. A collaborative approach is essential in order to improve targeted cancer prevention, screening, treatment and research in this group of people and their families.The purpose of the Partnership is to:
- Provide a cohesive research network for Familial Cancer Centres (FCCs) operating within Australia, transforming their clinical practice into a research resource
- Create the mechanism for translating and evaluating research firmly fixed on outcomes to improve the health of people with a hereditary predisposition to cancer
- Create an environment to facilitate research collaborations and train the next generation of familial cancer researchers
ICCon will use a collaborative approach over five years (2013-2017) to specifically address a number of Research Priorities in the familial cancer field:
- Research Priority 1: Develop a national infrastructure to connect the inherited cancer community, including clinicians and researchers
- Research Priority 2: Develop a national program to identify people at risk of heritable cancers
- Research Priority 3: Improve the accuracy of inherited cancer risk predictions
- Research Priority 4: Improve the knowledge of and access to effective cancer risk management strategies by: (i) National implementation of eviQ guidelines, (ii) Optimisation of medical prevention strategies for cancer
Cancer Council NSW
Associate Professor Gillian Mitchell
Ms Lyon Mascarenhas
Email: [email protected]
Publications & presentations
Chen Y, Peate M, Kaur R, Meiser B, Wong T, Kirk J, Ward R, Goodwin A, Macrae F, Hiller, J, Trainer A, Mitchell G (2017). Exploring clinicians’ attitudes about using aspirin for risk reduction in people with Lynch Syndrome with no personal diagnosis of colorectal cancer. Familial Cancer 16(1): 99-109.
Sutherland S, Meiser B, Mitchell G, Peate M, Wong T, Kaur R, Goodwin A. Barriers to Prescription of Tamoxifen as a risk reducing medication. (Oral Presentation and Media Interview) COSA's 43rd Annual Scientific Meeting 2016 November, Gold Coast, Australia.
Petelin L, Trainer A, Liew D, James P, Mitchell G. A systematic review of comparative effectiveness models and economic evaluations for cancer risk management strategies in BRCA1/2 mutation carriers. COSA's 43rd Annual Scientific Meeting 2016 November, Gold Coast, Australia.
Mascarenhas L,Boussioutas A, Shanley S, Ward R, Pachter N, Macrae F, Fox S, Mitchell G ,Duxbury E, Buchanan D, Spurdle A, Driessen R. A survey of the current provision of screening tumours for mismatch repair deficiency in Australia: An Inherited Cancer Connect Partnership (ICCon) initiative. Poster Session: RACS Annual Scientific Congress 2016 May,Brisbane, Australia
Mitchell G, Goodwin A. Risk reducing medication for cancer prevention - a survey of Australian specialists. Familial Aspects of Cancer 2015 Research and Practice; 2015 Aug 25-28; Kingscliffe, Australia
Mitchell G, Campbell I, Dawkins H, Fox S, Hiller J, James P, Kirk J, Lindeman G, Macrae F, McGauhran J, Meiser B, Pachter N, Saunders C, Scott C, Suthers G, Trainer A, Ward R, Young MA, ICCon Collaborators. An Introduction to ICCon - Inherited Cancer Connect Partnership. Poster Session: COSA's 40th Annual Scientific Meeting; 2013 Nov 12-14; Adelaide, Australia